Loading patent…
AssigneeDuke University
InventorsJonathan Stamler, Eric Toone, Andrew Gow
Estimating the term…
Treatment of pulmonary disorders associated with hypoxemia and/or smooth muscle constriction and/or inflammation comprises administering into the lungs as a gas a compound with an NO group which does not form NO2/NOx in the presence of oxygen or reactive oxygen species at body temperature. Treatment of cardiac and blood disorders, e.g., angina, myocardial infarction, heart failure, hypertension, sickle cell disease and clotting disorders, comprises administering into the lungs as a gas, a compound which reacts with cysteine in hemoglobin and/or dissolves in blood and has an NO group which is bound in said compound so that it does not form NO2/NOx in the presence of oxygen or reactive oxygen species at body temperature. Exemplary of the compound administered in each case is ethyl nitrite. Treatment of patient in need of improved oxygenation, blood flow of and/or thinning of blood comprises providing in the patient a therapeutic amount of red blood cells loaded with nitrosylated hemoglobin. A method is directed to screening drugs that increase level of nitrosoglutathione in airway lining fluid.
A method for treating a pulmonary disorder associated with hypoxemia and/or smooth muscle constriction and/or inflammation in the lungs in a patient having such disorder, said method comprising delivering into the lungs of said patient as a gas, a therapeutically effective amount of a compound having an NO group and having a hypoxemia relieving and smooth muscle constriction relieving and/or anti-inflammatory or inflammation defending effect with said NO group being bound in said compound so that it does not form NO2 or NOx in the presence of oxygen or reactive oxygen species at body temperature.
A method for treating a cardiac disorder which is characterized by ischemia, pump failure and/or afterload increase in a patient having such disorder, said method comprising delivering into the lungs of said patient as a gas, a therapeutically effective amount of compound which reacts with cysteine in hemoglobin and/or dissolves in blood and has an NO group which is bound in said compound so that it does not form NO2 or NOx in the presence of oxygen or reactive oxygen species at body temperature.
A method for treating a blood disorder which is ameliorated by treatment with NO in a patient having said disorder, said method comprising delivering into the lungs of said patient as a gas, a therapeutically effective amount of a compound which reacts with cysteine in hemoglobin and/or dissolves in blood and has an NO group which is bound in said compound so that it does not form NO2 or NOx in the presence of oxygen or reactive oxygen species at body temperature.
A method for treating a patient in need of improvement in tissue oxygenation or dilation of a blood vessel or inhibition of clotting, said method comprising providing in the patient a therapeutic amount of red blood cells loaded with nitrosylated hemoglobin, thereby to cause improved oxygen delivery or blood flow.
Blood containing red blood cells loaded with nitrosylated hemoglobin, outside the body.
A method for screening for drug that increase level of nitrosoglutathione in airway lining fluid, comprising administering putative drug in gas form into the lung of a model animal, sampling airway lining fluid and assaying for nitrosoglutathione in the sample obtained by sampling.
Dependencies are inferred from the claim text.